© 2018 by the Melbourne Brain Centre. Created by MStranslate

  • Facebook App Icon

BRAIN TUMOURS

In over 60% of patients with brain tumours, the disease is incurable, with the average life expectancy being less than one year despite the best available treatments.

The brain tumour research group investigates the basic molecular and cellular events that lead to the development of brain cancer to identify potential novel targets for biological therapies. The MBC-RMH Brain Tumour research unit’s clinical and translational research programs involve oncology, trauma, neurophysiology of vision and cerebrovascular disease, particularly subarachnoid hemorrhage. These are undertaken in collaboration with various departments of the the University of Melbourne, RMH and VCCC and international groups including Harvard University, The University of Auckland and The Hebrew University in Jerusalem.

RESEARCHERS

Associate Professor Kate Drummond

 

Associate Professor Kate Drummond is Director of Neurosurgery at The Royal Melbourne Hospital and Head of Central Nervous System Tumours for the VCCC. Her chief research and clinical interests are in the biology and clinical management of brain tumours. She serves on a number of national cancer and brain tumour groups and boards.

Kate is Neurosurgery Editor of the Journal of Clinical Neuroscience and Chief Examiner in Neurosurgery for the Royal Australasian College of Surgeons. She is the Deputy Chair of the Royal Australasian College of Surgeons, Section of Women in Surgery, and has received the RACS Medal for Services to RACS.

Dr Andrew Morokoff

 

Dr Andrew Morokoff is an academic neurosurgeon at Royal Melbourne Hospital and senior lecturer in the Department of Surgery University of Melbourne and is Head of the RMH Brain Tumour & Epilepsy Laboratory.

Highlights

 

  • Joining the International Collaboration on Meningiomas (ICOM), an international collaborative effort to improve treatment and quality of life in these tumours

  • Multiple studies into the biology and treatment of brain tumours including to develop a “liquid biopsy” using microRNA to diagnose brain tumours and monitor treatment

  • Completion of the Australian Genomics and Clinic Outcomes or Glioma study recruitment with RMH the second highest recruiter in Australia. Results in 2019.

  • Development of Phase 0 clinical trial protocol for novel agent

  • Largest ongoing quality of life study on brain tumours in the world

  • A prospective study of language impairment and recovery following surgery for brain tumours - NHMRC funded

  • Clinical advances include the commissioning of the intraoperative MRI scanner - making surgery for our patients even safer

  • De novo GBM - VERTU - PARP inhibitor in GBM (nearly completed accrual), Nutmeg - immunotherapy agent in GBM (about to have our start up)

  • Recurrent GBM - AMG596 - first in human BITE EGFRvIII study (2nd patient in the world put on at RMH)

  • 2017-2021 EpiBios4Rx (NIH funded $21M international multi-centre study into epilepsy monitoring in severe neurotrauma. Morokoff (PI) of Royal Melbourne Hospital, University of Melbourne site.

RESEARCH INSIGHTS

Brain Tumour Research